Comparative pharmacokinetics of zidovudine and its toxic catabolite 3′-amino-3′-deoxythymidine in HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 12, Issue 3, 1996, Pages 229-233

  Zhou, Xiao Jian ^a   Sommadossi, Jean Pierre ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' AMINO 3' DEOXYTHYMIDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ADULT; DIDEOXYNUCLEOSIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HUMANS; MALE; ZIDOVUDINE;

EID: 0030062865     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.229     Document Type: Review

References (22)

1. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, Phil D, King D, and the AZT Collaborative Working Group: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:185-191.
2. Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL, and the AZT Collaborative Working Group: Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988;319:1573-1578.
3. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS, Jackson GG, Durack DT, Phil D, Nusinoff-Lehrman S, and the AZT Collaborative Working Group: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:192-197.
4. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Reichman RC, Bartlett JA, Hirch MS, Murrphy RL, Hardy WD, Soeiro R, Fischl MA, Bartlett JG, Merigan TC, Hyslop NE, Richman DD, Valentine FT, Corey L, and the AIDS Clinical Trial Group of the National Institute of Allergy and Infectious Diseases: Zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med 1990;322:941-949.
5. Sommadossi JP and Carlisle R: Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother 1987;31:452-454.
6. Dainiak N, Worthington M, Riordan MA, Kreczko S, and Goldman L: 3′-Azido-3′-deoxythymidine (AZT) inhibits proliferation in vitro of human haematopoietic progenitor cells. Br J Haematol 1988;69:299-304.
7. Ganser A, Greher J, Volkers B, Staszewski S, and Hoelzer D: Inhibitory effects of azidothymidine, 2′,3′-dideoxyadenosine, and 2′,3′-dideoxycidine on in vitro growth of hematopoitic progenitor cells from normal persons and from patients of AIDS. Exp Hematol 1989;17:321-325.
8. Abraham NG, Bucher D, Niranjan U, Brown AC, Lutton JD, Distenfeld A, Ahmed T, and Levere RD: Microenvironmental toxicity of azidothymidine: Partial sparing with hemin. Blood 1989;74:139-144.
9. Sommadossi JP, Carlisle R, and Zhou Z: Cellular pharmacology of 3′-azido-3′-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells. Mol Pharmacol 1989;36:9-14.
10. Bridges EG, Faraj A, and Sommadossi JP: Inhibition of mammalian DNA polymerase-associated 3′ to 5′ exonuclease activity by 5′-monophosphates of 3′-azido-3′-deoxythymidine and of 3′-amino-3′-deoxythymidine. Biochem Pharmacol 1993;45:1571-1576.
11. Weidner DA and Sommadossi JP: 3′-Azido-3′-deoxythymidine inhibits globin gene transcription in butyric acid-induced K562 human leukemia cells. Mol Pharmacol 1990;38:797-804.
12. Stagg MP, Cretton EM, Lauren K, Diasio RB, and Sommadossi JP: Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine. Clin Pharmacol Ther 1992;51:668-676.
13. Blum MR, Liao S, Good SS, and de Miranda P: Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988;85(Suppl. 2A):189-194.
14. Good SS, Koble CS, Crouch R, Jonhson RL, Rideout JL, and de Miranda P: Isolation and characterization of an ether glucuronide of zidovudine, a major metabolite in monkeys and humans. Drug Metab Dispos 1990;18:321-326.
15. Cretton EM, Xie MY, Bevan RI, Goudgaon NM, Schinazi RF, and Sommadossi JP: Catabolism of 3′-azido-3′-deoxythymidine in hepatocytes and liver microsomes with evidence of formation of 3′-amino-3′-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol Pharmacol 1990;39:258-266.
16. Cretton EM, Schinazi RF, McClure HM, Anderson DC, and Sommadossi JP: Pharmacokinetics of 3′-azido-3′-deoxythymidine and catabolism in rhesus monkeys. Antimicrob Agents Chemother 1991;35:801-807.
17. Tadepalli S, Quinn R, Puckett LD, Orf JW, Goldensoph, and Donner JE: Adaptation of ZDV-Trac for simultaneous monitoring of AZT and GAZT. In: Proceedings of the American Association of Clinical Chemistry Annual Meeting, 1989, abstract 40.
18. Zhou XJ and Sommadossi JP: Quantification of 3′-amino-3′-deoxythymidine, a toxic catabolite of 3′-azido-3′-deoxythymidine (zidovudine) in human plasma by high performance liquid chromatography using precolumn derivatization with fluorescamine and fluorescence detection. J Chromatogr B 1994;656:389-396.
19. Laurent P, Cretton EM, Pacidi M, and Sommadossi JP: Reduction of 3′-azido-3′-deoxythymidine to 3′-amino-3′-deoxythymidine in human liver microsomes and its relationship to cytochrome P450. Clin Pharmacol Ther 1993;54:168-176.
20. Fischer PH, Lin TS, and Prusoff WH: Reversal of the cytotoxicity of 3′-amino-3′-deoxythymidine by pyrimidine deoxyribonucleosides. Biochem Pharmacol 1979;28:991-994.
21. Lin T, Fischer PH, and Prusoff WH: Effect of 3′-amino-3′-deoxythymidine on L1210 and P388 leukemias in mice. Biochem Pharmacol 1982;31:125-128.
22. Chen MS, Woods KL, and Prusoff WH: Molecular basis of the antineoplastic activity of 3′-amino-3′-deoxythymidine. Mol Pharmacol 1984;25:441-445.